Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Operating Expenses (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Operating Expenses for 16 consecutive years, with $18.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 3.94% to $18.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.9 million, a 22.0% decrease, with the full-year FY2025 number at $74.9 million, down 7.7% from a year prior.
  • Operating Expenses was $18.5 million for Q4 2025 at Anika Therapeutics, down from $18.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $35.4 million in Q1 2023 to a low of -$18.9 million in Q4 2023.
  • A 5-year average of $20.1 million and a median of $21.6 million in 2021 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 470.32% in 2021, then crashed 146.33% in 2022.
  • Anika Therapeutics' Operating Expenses stood at $27.3 million in 2021, then plummeted by 146.33% to -$12.6 million in 2022, then tumbled by 49.9% to -$18.9 million in 2023, then soared by 194.2% to $17.8 million in 2024, then rose by 3.94% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Operating Expenses are $18.5 million (Q4 2025), $18.8 million (Q3 2025), and $18.5 million (Q2 2025).